Idiopathic hypersomnia (IH) is an elusive disease state with a significant impact on quality of life (QoL). Clinicians often fail to recognize how this impact on QoL affects both patient and family, and how IH disrupts one’s ability to live a full life. Unfortunately, clinician’s struggle to apply novel treatments into practice and lack guidance as recent AASM guidelines to not include most up-to-date data for the optimal treatment of IH. Additionally, in August 2021, lower-sodium oxybate (LXB) was the first treatment approved for IH, however, understanding of this novel treatment is still lacking.
In this CMEO BriefCase entitled, Choosing Treatment: Matching Needs to Therapy, expert faculty will engage in a case-based discussion on how to best utilize the latest efficacy and safety data to integrate novel therapies into clinical practice to mitigate the impact of IH.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2023-07-24 05:00:00
- End Date: 2023-07-24 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Jazz Pharmaceuticals, Inc. - Amount: 73334.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Internal Medicine, Sleep Medicine